869347-26-2Relevant articles and documents
Fragment based discovery of arginine isosteres through REPLACE: Towards non-ATP competitive CDK inhibitors
Premnath, Padmavathy Nandha,Liu, Shu,Perkins, Tracy,Abbott, Jennifer,Anderson, Erin,McInnes, Campbell
, p. 616 - 622 (2014/01/17)
In order to develop non-ATP competitive CDK2/cyclin A inhibitors, the REPLACE strategy has been applied to generate fragment alternatives for the N-terminal tetrapeptide of the cyclin binding motif (HAKRRLIF) involved in substrate recruitment prior to phosphotransfer. The docking approach used for the prediction of small molecule mimics for peptide determinants was validated through reproduction of experimental binding modes of known inhibitors and provides useful information for evaluating binding to protein-protein interaction sites. Further to this, potential arginine isosteres predicted using the validated LigandFit docking method were ligated to the truncated C-terminal peptide, RLIF using solid phase synthesis and evaluated in a competitive binding assay. After testing, identified fragments were shown to represent not only appropriate mimics for a critical arginine residue but also to interact effectively with a minor hydrophobic pocket present in the binding groove. Further evaluation of binding modes was undertaken to optimize the potency of these compounds. Through further application of the REPLACE strategy in this study, peptide-small molecule hybrid CDK2 inhibitors were identified that are more drug-like and suitable for further optimization as anti-tumor therapeutics.
Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. Design, synthesis, and biological evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity
Fattorusso, Caterina,Gemma, Sandra,Butini, Stefania,Huleatt, Paul,Catalanotti, Bruno,Persico, Marco,De Angelis, Meri,Fiorini, Isabella,Nacci, Vito,Ramunno, Anna,Rodriquez, Manuela,Greco, Giovanni,Novellino, Ettore,Bergamini, Alberto,Marini, Stefano,Coletta, Massimo,Maga, Giovanni,Spadari, Silvio,Campiani, Giuseppe
, p. 7153 - 7165 (2007/10/03)
Pyrrolobenzoxazepinones (PBOs) represent a new class of human immunodeficiency virus type 1 (HIV-1) nonnucleoside reverse transcriptase (RT) inhibitors (NNRTIs) whose prototype is 5. Molecular modeling studies based on the X-ray structures of HIV-1 RT pro
